Use of benzodiazepines and Z-drugs is associated with a 29% higher odds of developing Alzheimer’s disease, according to a systematic review and meta-analysis published in Drugs. However, the association varies by drug class, duration of action, and how the diagnosis is defined, and the authors caution that residual confounding and reverse causation limit causal interpretation.
What they found
The review included 13 studies with a combined 721,354 participants. All studies enrolled adults without dementia at baseline and compared benzodiazepine (BZD) or Z-drug users with non-users.
- Overall association: Sedative-hypnotic use was associated with higher odds of Alzheimer’s disease (OR 1.29; 95% CI 1.10-1.53). Hazard ratio estimates were attenuated and not statistically significant (HR 1.17; 95% CI 0.87-1.58).
- By drug class: BZDs overall (OR 1.21), Z-drugs (OR 1.14), and short-acting agents (OR 1.19) were each associated with higher odds. Broad-acting BZDs showed no association (OR 1.01).
- By age: Higher odds were seen in individuals under 75 years (OR 1.36) but not in those aged 75 and older (OR 1.14, not statistically significant).
- By diagnostic method: Studies using ICD-based definitions showed stronger associations (OR 1.47) than those using clinical diagnostic criteria (OR 1.13).
Meta-regression identified drug class and publication year as significant moderators. Quality of evidence ranged from very low to moderate, with risk of bias driven mainly by residual confounding and exposure misclassification.
Why it matters
Sedative-hypnotics are among the most widely prescribed medications in older adults, often for insomnia and anxiety. The question of whether they contribute to dementia risk has been debated for years, with conflicting results across individual studies. This large meta-analysis clarifies that an association exists, but that it is modest, heterogeneous, and heavily influenced by study design.
The finding that broad-acting BZDs — which include longer half-life agents like diazepam — showed no association, while short-acting agents did, complicates any simple causal narrative. It may reflect differences in prescribing patterns, underlying conditions, or the populations that receive each class.
Clinically, the results reinforce the principle of cautious prescribing in older adults: using the lowest effective dose for the shortest necessary duration, and considering non-pharmacologic alternatives for insomnia.
Limits
Observational studies cannot rule out reverse causation — prodromal Alzheimer’s-related sleep disruption may drive sedative-hypnotic use, rather than the drugs causing disease. Exposure was often assessed at a single time point. High heterogeneity (I2 = 86.5% for ORs) suggests substantial differences across study populations and methods. The GRADE certainty was rated very low to moderate.
Bottom line
Use of benzodiazepines and Z-drugs is associated with a modest increase in the odds of developing Alzheimer’s disease, but the association varies by drug class and is susceptible to confounding. The finding supports judicious prescribing but does not establish causation.
Source
“Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer’s Disease: A Systematic Review, Meta-Analysis and Meta-Regression.” Drugs, July 2026; 86(7): 1103-1119. DOI: 10.1007/s40265-026-XXXXX